INFORMATION DISCLO	SURE
STATEMENT BY APPLI	CANT
( Not for submission under 37 CF	FR 1.99)

Application Number		10588126
Filing Date		2006-08-23
First Named Inventor	Yehu	dit NATAN
Art Unit		1654
Examiner Name	J.E. RUSSEL	
Attorney Docket Numb	er	27586U

			Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	4018911		1977-04-19	Lionetti, et al.	
	2	4874690		1989-10-17	Goodrich, Jr. et al.	
	3	5059518		1991-10-22	Kortright, et al.	
	4	5071598		1991-12-10	Baldeschwieler, et al.	
	5	5364756	A	1994-11-15	Livesey, et al.	
	6	5629145	А	1997-05-13	Meryman	
	7	5827741	А	1998-10-27	Beattie, et al.	
	8	5869092	А	1999-02-09	Hays, et al.	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10588126		
Filing Date		2006-08-23		
First Named Inventor	Yehud	dit NATAN		
Art Unit		1654		
Examiner Name	J.E. R	USSEL		
Attorney Docket Number		27586U		

	9	5873254	A	1999-02	2-23	Arav				
	10	6073540	A	2000-06	5-13	Garrett				
	11	6723497	B2	2004-04	I-20	Wolkers, et al.				
If you wis	h to a	⊥ dd additional U.S. Pate	nt citatio	n inform	ation pl	Lease click the	Add button.		Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>		Publication Name of Patentee or Applicant R		Relev	ages,Columns,Lines where elevant Passages or Relevant gures Appear		
	1	20070077237	A1	2007-04	1-05	Damari, et al.				
	2	20070277535	A1	2007-12	?-06	Uri, et al.				
	3	20080120984	A1	2008-05	5-29	Shaham, et al.				
If you wis	h to a	dd additional U.S. Publ	ished Ap	plication	citation	n information p	lease click the Ad	d butto	n Add	
				FOREIG	GN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T5
	1	1279356	GB			1972-06-28	American Hospital Corporation	Supply		

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10588126		
Filing Date		2006-08-23		
irst Named Inventor	Yehud	dit NATAN		
Art Unit		1654		
Examiner Name	J.E. R	RUSSEL		
Attorney Docket Number		27586U		

		1906603	SU.		1002.04.07	UK NII PLEMENNOMU		×
		7000002				DELU V ZHIVO		
	3	0668013	EP	A2	1995-08-23	Nippon Telegraph and Telephone Corporation		
	1.	2020100155	15		2000 07 44	Livestock Improvement		
		2000109155	131	^	2000-07-11	Ass of J		×
	5	1057405	EP	A1	2000-12-06	MG Pharmacy Ltd.		
	6	0201952	wo	A1	2002-01-10	Wada, et al.		×
	7	03020874	wo	A2	2003-03-13	Interface Multigrad Technology Ltd.		
	8	9300806	wo	A1	1993-01-21	Quadrant Holdings Cambridge Limited		
	9	9739104	wo	A1	1997-10-23	Osiris Therapeutics, Inc., et al.		
	10	2008032314	wo	A2	2008-03-20	I.M.T. Interface Multigrad Technology Ltd.		
	11	9960849	wo	A1	1999-12-02	Lifecell Corporation		
If you wi	ish to a	dd additional Foreign F				lease click the Add buttor		_
			NON-PATE	NTIITI	FRATURE DO	CUMENTS	Remove	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JER/

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

Application Number		10588126		
iling Date		2006-08-23		
irst Named Inventor Yehud		dit NATAN		
Art Unit		1654		
xaminer Name	J.E. R	RUSSEL		
Attorney Docket Numb	er	27586U		

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
	1	LELKENS, et al. "Stability after thawing of RBCs frozen with the high- and low-glycerol method", Transfusion, 2003, Vol.43, pp.157-164, The Military Blood Bank, Netherlands.	
	2	CHOW, et al. "Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E1", Cancer Epidemiology, Biomarkers & Prevention, 2001, Vol.10, pp.53-58, The University of Arizona.	
	3	DE KORTE, et al. "Quality determinants of erythrocyte destined for transfusion", Cellular and Molecular Biology, 2004, Vol.50(2), pp.187-195.	
	4	GRINBERG, et al. "Protective effects of tea polyphenois against oxidative damage to red blood cells", Biochemical Pharmacology, 1997, Vol.54, pp.973-978, Elsevier Science Inc.	
	5	GALATI, et al. "Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics", Toxicology, 2002, Vol.177, pp.91-104, Elsevier Science Ireland Ltd.	
	6	CHEN, et al. "Beneficial effect of intracellular trehalose on the membrane integrity of dried mammalian cells", Cryobiology, 2001, Vol.43, pp.168-181, Elsevier Science (USA).	
	7	FUJIKI, et al. * Mechanistic findings of green tea as cancer preventive for humans*, P.S.E.B.M., 1999, Vol.220, pp.225-228, Society for Experimental Biology and Medicine.	
	8	CROWE, et al. "Stabilization of membranes in human platelets freeze-dried with trehalose", Chemistry and Physics of Lipids, 2003, Vol.122, pp.41-52, Elsevier Science Ireland Ltd.	
	9	SATPATHY, et al. "Loading red blood cells with trehalose: a step towards biostabilization", Cryobiology, 2004, Vol.49, pp.123-136, Eisevier Inc.	
	10	KUMAZAWA, et al. "Direct evidence of interaction of a green tea polyphenol, epigallocatechin gallate, with lipid bilayers by solid-state nuclear magnetic resonance", Biosci. Biotechnol. Beochem., 2004, Vol.68(6), pp.1743-1747.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JER/

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
( Not for submission under 37 CFR 1.99)

Application Number		10588126		
Filing Date		2006-08-23		
First Named Inventor Yehu		dit NATAN		
Art Unit		1654		
Examiner Name	J.E. R	J.E. RUSSEL		
Attorney Docket Numb	er	27586U		

	11	AHLENSTIEL, et al. "Bioflavonoids attenuate renal proximal tubular cell injury during cold preservation in Euro-Collins and University of Wisconsin solutions", Kidney International, 2003, Vol.63, pp.554-563, International Society of Nephrology.									
	12	SUGANUMA, et al. "Greeen tea and cancer chemoprevention", Mutation Research, 1999, Vol.428, pp.339-344, Elsevier Science B.V.									
	13	ISBRUCKER, et al. "Safety studies on epigallocatechin gallate (EGCG) preparations. Part 3. teratogenicity and reproductive toxicity studies in rats. Food Chemical Toxicology, 2006, Vol.44, pp.651-661. (Abstract)									
	14	XP-002337043, Derwent, "Preservation solution for cells and tissues contains polyphenol as effective componenet".									
	15	XP-002337044, Derwent, "Composition for preservative of animal cell, organs such as skin, blood vessel, cornea, kidney, heart, liver, lungs, placenta or pancreas, contains preset amount of epigallocatechin gallate as active ingredient".									
If you wis	n to ac	ld additional non-patent literature document citation information please click the Add button	Add								
		EXAMINER SIGNATURE									
Examiner	xaminer Signature / Jeffrey Russel/ Date Considered 01/14/2010										
		itial if reference considered, whether or not citation is in conformance with MPEP 609. Drav									

¹ See Kind Codes of USPTO Patent Documents at <a href="https://www.USPTO.GOV">www.USPTO.GOV</a> or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Lapanese patent documents, the indication of the year of the reign of the Emporor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.